Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













Aripiprazole/sertraline







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Aripiprazole/sertraline
Combination of
AripiprazoleAtypical antipsychotic
SertralineSelective serotonin reuptake inhibitor
Clinical data
Other namesASC-01
Routes of
administration		By mouth
Legal status
Legal status

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulationofaripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]

See also[edit]

References[edit]

  1. ^ a b c "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  • ^ Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y (August 2018). "Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder". Psychiatry and Clinical Neurosciences. 72 (8): 591–601. doi:10.1111/pcn.12663. PMID 29660207. S2CID 4958169.
  • ^ "Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight". adisinsight.springer.com.



    • Stub icon

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Aripiprazole/sertraline&oldid=1183561413"
    Categories: 
    ●Antidepressants
     ●Atypical antipsychotics
     ●Combination psychiatric drugs
     ●Abandoned drugs
     ●Nervous system drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Chemical articles without CAS registry number
     ●Articles without EBI source
     ●Chemical pages without ChemSpiderID
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
     ●Drugs that are a combination of chemicals
     ●All stub articles
      


    ●This page was last edited on 5 November 2023, at 02:21 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki